ReviewBioorganic & medicinal chemistry letters2023
Overcoming intrinsic resistance in gram-negative bacteria using small molecule adjuvants.
Review in Bioorganic & medicinal chemistry letters, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 28 citations in OpenAlex.
- IMD-0354 optimization generates potent colistin adjuvants with in vivo activity and reduced eukaryotic toxicity.European journal of medicinal chemistry · 2026Article
- Repurposing Ponatinib Hydrochloride as an Antibacterial and Antibiofilm Agent Against Multidrug-ResistantMicroorganisms · 2026Article
- Bacterial adaptation to essential oils and their main compounds in food systems: mechanisms related to antibacterial resistance.NPJ science of food · 2026Review
- Discovery of a Novel Benzothiophene Inhibitor of Penicillin-Binding Protein 2 with Potent Gram-Positive Activity.Antibiotics (Basel, Switzerland) · 2026Article
- Rapid Optical Nanomotion-Based Antibiotic Susceptibility Testing of Kombucha-Associated Acetic Acid Bacteria andFoods (Basel, Switzerland) · 2026Article
- Mechanisms of Bacterial Resistance and Innovative Strategies to Overcome Antimicrobial Resistance.Antibiotics (Basel, Switzerland) · 2026Review
- Evaluation of the effects of hybrids of metronidazole and eugenol analogues as inhibitors of the Staphylococcus aureus NorA efflux pump: an in vitro and in silico analysis.Folia microbiologica · 2026Article
- Biochemical and genomic characterization of last-resort antibiotic resistance and oxidant tolerance in environmentalFrontiers in toxicology · 2026Article
- Antimicrobial resistance in dental unit waterlines: a scoping review of microbial diversity, resistance patterns, and knowledge gaps.Frontiers in oral health · 2026Review
- Alternative Approach to Sequence-Specific Recognition of DNA: Cooperative Stacking of Dication Dimers─Sensitivity to Compound Curvature, Aromatic Structure, and DNA Sequence.ACS chemical biology · 2025Article
- Amidine containing compounds: Antimicrobial activity and its potential in combating antimicrobial resistance.Heliyon · 2024Review
- Identification of a 2-Aminobenzimidazole Scaffold that Potentiates Gram-Positive Selective Antibiotics Against Gram-Negative Bacteria.Chembiochem : a European journal of chemical biology · 2024Article
- Antimicrobial Indole-3-Carboxamido-Polyamine Conjugates Target Bacterial Membranes and Are Antibiotic Potentiators.Biomolecules · 2024Article
- Macrolide resistance inFrontiers in microbiology · 2024Article
- Mechanism of antibacterial resistance, strategies and next-generation antimicrobials to contain antimicrobial resistance: a review.Frontiers in pharmacology · 2024Review
- Combating antimicrobial resistance: the silent war.Frontiers in pharmacology · 2024Review
- War and peace: exploring microbial defence systems as a source of new antimicrobial therapies.Frontiers in pharmacology · 2024Review
- Bioprospecting of unexplored halophilic actinobacteria against human infectious pathogens.3 Biotech · 2023Review
- Screening of Phytochemical, Antimicrobial, and Antioxidant Properties ofLife (Basel, Switzerland) · 2023Article
- Dimeric 2-aminoimidazoles are highly active adjuvants for gram-positive selective antibiotics against Acinetobacter baumannii.European journal of medicinal chemistry · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Gram-negative bacteria are intrinsically resistant to many classes of antibiotics, predominantly due to the impermeability of the outer membrane and the presence of efflux pumps. Small molecule adjuvants that circumvent these resistance mechanisms have the potential to expand therapeutic options for treating Gram-negative infections to encompass antibiotic classes that are otherwise limited to treating Gram-positive infections. Adjuvants that effect increased antibiotic permeation, either by physical disruption of the outer membrane or through interference with synthesis, transport, or assembly of membrane components, and adjuvants that limit efflux, are discussed as potential avenues to overcoming intrinsic resistance in Gram-negative bacteria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.